A recent post hoc analysis assesses whether PSA changes can predict survival outcomes in patients with metastatic or very high risk nonmetastatic prostate cancer.
Detailed price information for Candel Therapeutics Inc (CADL-Q) from The Globe and Mail including charting and trades.
Drs. Pallabi Mustafi and Ruben Raychaudhuri at Fred Hutch Cancer Center recently received Young Investigator Awards from the ...
Most prostate cancers rely on male sex hormones, known as androgens, to grow. As a result, standard treatment focuses on ...
ASPIRE trial explores survival benefits of adding chemotherapy to standard prostate cancer treatment
The Alliance for Clinical Trials in Oncology is now enrolling patients in the ASPIRE trial (A032302)-a large-scale, phase III ...
In August 2025, the FDA accepted the supplemental New Drug Application (sNDA) for Truqap in combination with abiraterone and ADT based on positive results from the CAPItello-281 Phase III trial, ...
The drug delivery peptide embeds itself in cancer cell membranes and shrinks human tumors in mice more safely than the drug ...
Benjamin Netanyahu goes public about his prostate cancer diagnosis for the first time ever. Here is what the Israeli PM said amid West Asia war ceasefire talks.
The facilities were inaugurated by Tirumala Tirupati Devasthanams (TTD) chairman B.R. Naidu under the Sri Balaji ...
The US Food and Drug Administration’s (FDA) Oncologic Drugs Advisory Committee (ODAC) has recognized a favorable benefit risk profile for AstraZeneca’s TRUQAP® (capivasertib) in combination with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results